Aardvark Therapeutics, Inc. Reports Exploratory Efficacy Data from HERO and OLE Trials

Aardvark Therapeutics, Inc. (NASDAQ: AARD) issued a press release and filed an 8-K reporting exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. The company also hosted an investor webinar to discuss the data.